OSM-0205

OSM-0205 is a novel, patent-protected investigational drug developed to prevent chemotherapy-induced peripheral neuropathy (CIPN) and potentially chemotherapy-induced cognitive impairment (CICI). It is designed to modulate intracellular calcium via a unique mechanism based on the research of Dr. Barbara Ehrlich at Yale School of Medicine, focusing on neuronal calcium sensor-1 (NCS1). Taxane-based chemotherapies and other microtubule-disrupting agents can cause an off-target surge in intracellular calcium by binding to NCS1, which activates calpain and leads to neuronal dysfunction. OSM-0205 blocks this pathological calcium surge, prevents calpain activation, maintains NCS1 integrity, and protects neurons from damage. The drug is administered intravenously immediately prior to chemotherapy treatment. Clinical development is led by Osmol Therapeutics with initial focus on prevention of CIPN in breast cancer patients; it may also have potential for use with other solid tumor cancers treated with taxanes or antibody-drug conjugates containing microtubule-disrupting payloads[1][4][6][7].